Aclaris Therapeutics (ACRS) Non-Current Assets (2014 - 2026)

Aclaris Therapeutics' Non-Current Assets history runs 13 years deep, the most recent figure standing at $88.5 million for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 0.91% year-over-year to $88.5 million in Q1 2026; TTM through Mar 2026 was $312.5 million, a 12.75% increase from a year earlier, with the FY2025 full-year figure at $64.1 million, down 32.03% from the prior year.
• Non-Current Assets advanced to $88.5 million in Q1 2026 per ACRS's latest filing, from $64.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $102.7 million in Q2 2023 and bottomed at $11.1 million in Q3 2022.
• The 5-year median for Non-Current Assets is $64.1 million (2025), against an average of $60.5 million.
• Across the five-year window, Non-Current Assets tumbled 80.84% in 2022 and jumped 761.61% in 2023, its largest moves.
• Year by year, Non-Current Assets stood at $23.0 million in 2022, then jumped by 197.44% to $68.5 million in 2023, then soared by 37.68% to $94.4 million in 2024, then plunged by 32.03% to $64.1 million in 2025, then jumped by 37.96% to $88.5 million in 2026.
• Per Business Quant, the three latest ACRS Non-Current Assets figures stand at $88.5 million (Q1 2026), $64.1 million (Q4 2025), and $74.9 million (Q3 2025).